GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnGes Inc (TSE:4563) » Definitions » Gross-Profit-to-Asset %

AnGes (TSE:4563) Gross-Profit-to-Asset % : 1.09% (As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is AnGes Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. AnGes's annualized Gross Profit for the quarter that ended in Jun. 2024 was 円304.6 Mil. AnGes's average Total Assets over the quarter that ended in Jun. 2024 was 円27,852.5 Mil. Therefore, AnGes's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 1.09%.


AnGes Gross-Profit-to-Asset % Historical Data

The historical data trend for AnGes's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnGes Gross-Profit-to-Asset % Chart

AnGes Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.33 0.07 0.02 -0.06 0.06

AnGes Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.09 1.01 1.09 0.56

Competitive Comparison of AnGes's Gross-Profit-to-Asset %

For the Biotechnology subindustry, AnGes's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AnGes's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnGes's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where AnGes's Gross-Profit-to-Asset % falls into.



AnGes Gross-Profit-to-Asset % Calculation

AnGes's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=19.445/( (38820.711+28892.536)/ 2 )
=19.445/33856.6235
=0.06 %

AnGes's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=304.588/( (28029.48+27675.479)/ 2 )
=304.588/27852.4795
=1.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


AnGes Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of AnGes's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


AnGes Business Description

Industry
Traded in Other Exchanges
Address
7-7-15, Saito-asagi, 4F, Saito Bio-Incubator, Ibaraki, Osaka, JPN, 567-0085
AnGes Inc is a biopharmaceutical company. The company's development projects include - HGF plasmid, NFkB decoy oligonucleotide, and Therapeutic vaccine.

AnGes Headlines

No Headlines